A agilent.com: Rasio rega marang prakiraan pendapatan

Lambang korporat lan logo Agilent Technologies, Inc. (A)

Agilent Technologies is optimizing costs by sourcing basic electronics from external partners while maintaining its own R&D. The forward price-to-sales ratio clearly demonstrates the business valuation trend, with the current figure standing at 5.00. Agilent Technologies maintains its status as the gold standard in analytical chemistry. An impeccable image and the trust of the global scientific community make the brand a benchmark for diagnostic equipment precision.

A (Agilent Technologies, Inc.) riwayat Rasio rega marang pendapatan sing dikarepake saka 04.07.2022 nganti 13.11.2026

Rincian analitis perusahaan Agilent Corp (A)

- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
Analisis wiwitan perusahaan:Agilent A
Produk sing diprodhuksi Agilent Corp

The forward P/S ratio assesses the market value of a business relative to its projected revenue, identifying whether an asset is overbought or undervalued. By analyzing the projected P/S value, an investor determines the extent to which current capitalization is justified by future cash flows. For Agilent Technologies (A), this multiple reflects market confidence in the scaling of high-tech robotic assembly and the implementation of AI diagnostics, which are expected to ensure stable sales growth.

Pesaing Agilent Technologies (A)

Multiplikator Forward P/S DGX (Quest Diagnostics Incorporated)|Illumina Inc (ILMN) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|EXAS - Rasio rega marang prakiraan pendapatan|RVTY (Revvity Corp) - Kapitalisasi marang prakiraan pendapatan|BIO (Bio-Rad Laboratories) - Multiplikator forward rega marang pendapatan|NNNN: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan SHC|QDEL: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan OPK (OPKO Corp)|Rasio rega marang pendapatan sing dikarepake CDNA|Multiplikator Forward P/S MRVI (Maravai LifeSciences)|fulgentgenetics.com (FLGT) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Standard BioTools - Multiplikator Forward P/S|Cytek Biosciences Inc (CTKB) - Multiplikator forward rega marang pendapatan|OSUR: Multiplikator Forward P/S|Exagen - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan MDxHealth SA|Kapitalisasi marang prakiraan pendapatan LUCD (luciddx.com)|Rasio rega marang prakiraan pendapatan Prenetics Global (PRE)|IMDX - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Trinity Biotech TRIB|ProPhase Labs Corp - Rasio rega marang prakiraan pendapatan|AIMD - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep codiagnostics.com|HSCS: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Biomerica Inc. BMRA|CDIO (Cardio Diagnostics Holdings Inc.) - Multiplikator Forward P/S|Onconetix Corporation (ONCO) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S VRAX|BJDX - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Aspira Women's Health Inc. AWH|Rasio kapitalisasi marang dodolan sing dikarepake Accelerate Diagnostics Inc. (AXDX)|centogene.com - Multiplikator Forward P/S|ENZ - Multiplikator Forward P/S|fresh2.co (FRES) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Genetic Technologies Limited|ME (23andMe) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Psychemedics Corp. PMD